mamo.cz - Tamoxifen class drugs reduce breast cancer rates by more than a third in women at high risk
Why I'm taking tamoxifen to avoid breast cancer | MD Anderson Cancer Center
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models | npj Breast Cancer
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial - The Lancet
VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer | 2 Minute Medicine
Tamoxifen Accelerates Endothelial Healing by Targeting ERα in Smooth Muscle Cells | Circulation Research
Tamoxifen Not Associated With Higher Risk for Cataracts in Women With DCIS - Oncology Nurse Advisor
Combining Tamoxifen with Antidepressants: What You Need to Know
Cancers | Free Full-Text | TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1 | Nature Communications
Sex and Tamoxifen confound murine experimental studies in cardiovascular tissue engineering | Scientific Reports
Why So Many of Us Quit Taking Tamoxifen | FORCE: Facing our Risk of Cancer Empowered Blog
Why does tamoxifen work better in some women? | University of Michigan Rogel Cancer Center
Why women reject breast cancer preventing drug – new study
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial - The Lancet
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial - The Lancet
.jpg "Risk-Reducing Medications for Women at High-Risk of Breast Cancer: New Recommendations and Missed Opportunities | Public Health Sciences Division | Washington University in St. Louis")
Risk-Reducing Medications for Women at High-Risk of Breast Cancer: New Recommendations and Missed Opportunities | Public Health Sciences Division | Washington University in St. Louis
Tamoxifen - the start of something big - Cancer Research UK - Cancer News
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials - The Lancet Oncology
The Cost-Effectiveness of Adjuvant Tamoxifen Treatment of Hormone Receptor–Positive Early Breast Cancer Among Premenopausal and Perimenopausal Ghanaian Women - Value in Health Regional Issues
Cognitive Bias: The Downside of Shared Decision Making | JCO Clinical Cancer Informatics
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials - The Lancet
Why So Many of Us Quit Taking Tamoxifen | FORCE: Facing our Risk of Cancer Empowered Blog
